Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cladribine
Drug ID BADD_D00479
Description An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Indications and Usage For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
Marketing Status Prescription; Discontinued
ATC Code L01BB04; L04AA40
DrugBank ID DB00242
KEGG ID D01370
MeSH ID D017338
PubChem ID 20279
TTD Drug ID D05GJW
NDC Product Code 65129-1260; 67457-450; 63323-140; 42658-010; 54893-0115; 59605-3006; 58623-0037; 12502-4912; 0143-9871; 12502-5406; 44087-4000
Synonyms Cladribine | 2-Chlorodeoxyadenosine | 2-Chloro-2'-deoxyadenosine | 2'-Deoxy-2-chloroadenosine | Leustatin
Chemical Information
Molecular Formula C10H12ClN5O3
CAS Registry Number 4291-63-8
SMILES C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.0030.001095%
Abscess11.01.08.0010.000730%Not Available
Abscess bacterial11.02.01.027--Not Available
Administration site reaction08.02.04.011; 12.07.04.011--Not Available
Alanine aminotransferase increased13.03.01.0030.002189%
Alopecia23.02.02.0010.001825%
Altered state of consciousness17.02.04.001; 19.07.01.003--Not Available
Amyloidosis10.02.05.001--Not Available
Anaemia01.03.02.001--
Anxiety19.06.02.002--
Aplastic anaemia01.03.03.002--Not Available
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.0010.001095%
Arthritis15.01.01.001--
Aspartate aminotransferase increased13.03.01.0060.001460%
Asthenia08.01.01.001--Not Available
Ataxia08.01.02.004; 17.02.02.001--
Atrial fibrillation02.03.03.002--
B-cell lymphoma01.15.01.001; 16.28.01.0010.000190%Not Available
Back pain15.03.04.0050.001095%
Bacteraemia11.01.11.001--
Basal cell carcinoma16.03.02.001; 23.08.02.0010.001460%Not Available
Bladder cancer16.08.01.001; 20.03.04.0010.000190%Not Available
Blepharitis06.04.04.001; 23.03.04.012--Not Available
Blood bilirubin increased13.03.01.0080.000730%
Blood uric acid increased13.02.04.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene